SIRT3 and B-cell non-Hodgkin lymphoma: In particular, compounds 55 (IC50 SIRT2 0.25 μM and <25% inhibition at 50 μM against SIRT1 and SIRT3) and 56 (IC50 SIRT2 0.78 μM and <25% inhibition at 50 μM against SIRT1 and SIRT3) showed apoptotic as well as strong anti-proliferative properties against B-cell lymphoma cells.